Fluralaner (Bravecto)

Fluralaner, marketed under the brand name Bravecto, represents a significant advancement in feline ectoparasite control as a member of the isoxazoline class of antiparasitic medications. This innovative compound provides extended-duration protection against fleas and ticks, with a single topical application protecting cats for up to twelve weeks against fleas and certain tick species. The convenience of quarterly dosing rather than monthly treatment has made fluralaner a popular choice among cat owners and veterinary professionals seeking reliable, long-lasting flea and tick prevention with reduced treatment frequency.

Fluralaner works by inhibiting ligand-gated chloride channels in the nervous systems of arthropods, specifically targeting gamma-aminobutyric acid (GABA) receptors and glutamate receptors. This mechanism blocks the transfer of chloride ions across nerve cell membranes, resulting in uncontrolled neuromuscular activity that causes paralysis and death of fleas and ticks. The selective toxicity of fluralaner between insects and acarines versus mammals results from differential sensitivity of arthropod GABA receptors compared to mammalian GABA receptors, providing the basis for the medication's safety in cats while remaining highly lethal to parasites.

Bravecto for cats is available as a topical solution applied to the skin at the back of the neck using a convenient twist-and-use applicator. The medication is rapidly absorbed and distributed systemically throughout the cat's body. When fleas or ticks feed on a treated cat, they ingest fluralaner with the blood meal and are killed, typically within hours for fleas and within forty-eight hours for ticks. Bravecto kills one hundred percent of fleas within eight hours of treatment and provides greater than ninety-eight percent flea reduction within twelve hours for the full twelve-week protection period. The extended duration of action results from fluralaner's long half-life in cats, maintaining therapeutic concentrations throughout the dosing interval.

Bravecto is FDA-approved for cats and kittens six months of age and older weighing at least 2.6 pounds. The medication is indicated for the treatment and prevention of flea infestations and for the treatment and control of black-legged tick and Asian longhorned tick infestations for twelve weeks, with efficacy against American dog ticks for eight weeks. Safety studies have demonstrated that fluralaner is well-tolerated in cats, though as with all isoxazoline class medications, use with caution is advised in cats with a history of neurological disorders. Veterinary consultation ensures appropriate use of this prescription medication for individual feline patients.

Fluralaner (Bravecto) is indicated for the treatment and prevention of flea infestations caused by Ctenocephalides felis, the cat flea, for twelve weeks in cats and kittens six months of age and older weighing 2.6 pounds or greater. This primary indication addresses one of the most common parasitic problems affecting domestic cats, with a single application providing three months of continuous protection against new flea infestations while rapidly eliminating existing fleas on treated cats.

The medication is additionally indicated for the treatment and control of tick infestations, with efficacy against black-legged ticks (Ixodes scapularis) and Asian longhorned ticks (Haemaphysalis longicornis) for twelve weeks. American dog tick (Dermacentor variabilis) infestations are controlled for eight weeks following treatment. This tick control indication is particularly valuable for cats with outdoor access in geographic areas where tick-borne diseases are prevalent, as tick prevention reduces the risk of disease transmission to both cats and their human family members.

Fluralaner is commonly prescribed for cats suffering from flea allergy dermatitis, a condition where hypersensitivity to flea saliva causes severe skin irritation, hair loss, and intense itching even from minimal flea exposure. Clinical studies have demonstrated that cats with flea allergy dermatitis show significant improvement in skin condition following Bravecto treatment, with resolution of erythema, papules, crusts, alopecia, scales, and excoriation as a direct result of eliminating flea infestations. The rapid speed of kill and extended duration of protection make fluralaner particularly valuable for flea-allergic cats who require consistent, reliable flea control.

Bravecto Plus, a combination product containing fluralaner and moxidectin, extends the indications to include prevention of heartworm disease and treatment of intestinal parasites including roundworms and hookworms, providing comprehensive internal and external parasite protection in a single two-month application. This combination product is indicated for cats and kittens six months of age and older weighing at least 2.6 pounds.

Veterinarians select fluralaner when extended-duration flea and tick protection is desired, when owner compliance with monthly treatments has been problematic, or when the convenience of quarterly dosing offers advantages for specific patients or household situations. The medication is particularly valuable for cats that resist frequent medication administration, as the reduced dosing frequency minimizes treatment-associated stress for both cats and their owners.

Fluralaner (Bravecto) dosing for cats is weight-based, with the topical solution formulated to provide a minimum dose of 18.2 mg per pound (40 mg/kg) body weight. The medication is available in three tube sizes for cats: 112.5 mg for cats weighing 2.6 to 6.2 pounds, 250 mg for cats weighing 6.2 to 13.8 pounds, and 500 mg for cats weighing 13.8 to 27.5 pounds. Accurate cat weight determination ensures appropriate product selection and dosing for effective parasite control.

Bravecto should be administered as a single topical dose every twelve weeks to maintain continuous protection against fleas and ticks. The veterinarian determines the appropriate dosing schedule based on geographic location, flea and tick pressure, and individual patient needs. In areas with year-round parasite activity, four treatments annually provide continuous twelve-month protection. Treatment can begin at any time of year and continue year-round without interruption for optimal flea and tick prevention.

Administration of Bravecto topical solution involves parting the hair at the base of the cat's skull to expose the skin, then placing the tip of the applicator tube directly on the skin and squeezing to apply the entire contents. The solution should be applied to skin, not hair, to ensure proper absorption. For cats with dense or long coats, taking care to part the fur thoroughly before application ensures direct skin contact. The application site should not be rubbed or manipulated after application.

The medication is applied to a single spot at the back of the neck where cats cannot reach to groom, preventing oral ingestion of the topical product. If product contacts eyes or if the cat ingests some product through grooming another treated animal, mild and transient effects may occur but typically resolve without treatment. Cats should not be bathed or exposed to water for at least three days after application to allow adequate product absorption, though effectiveness following bathing after this period has not been evaluated.

For missed doses, Bravecto should be administered immediately and the twelve-week dosing schedule resumed from that date. There is no need for extra product or modified dosing after a missed treatment. If the treatment gap exceeds twelve weeks, cats may have reduced protection during the gap period, and new flea or tick infestations may occur. Returning to regular quarterly treatment restores full protection going forward.

Bravecto Plus, the combination product with moxidectin for heartworm prevention, is administered every eight weeks rather than twelve weeks to maintain continuous heartworm protection. Cat owners should follow the specific dosing schedule for the product prescribed, as Bravecto and Bravecto Plus have different administration intervals despite both containing fluralaner.

Fluralaner (Bravecto) is generally well-tolerated in cats, with most feline patients experiencing no adverse effects from treatment. In clinical field studies, the medication demonstrated a favorable safety profile with adverse reactions occurring infrequently. Understanding potential side effects helps cat owners monitor their pets appropriately and recognize any reactions requiring veterinary attention.

The most commonly reported adverse reactions in cats receiving Bravecto topical solution include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs or ulcerated lesions at or near the application site. These reactions were observed in clinical studies and post-marketing surveillance, occurring in a minority of treated cats. Most reported effects were mild and self-limiting, resolving without specific treatment. Transient application site reactions including temporary wetness, oily appearance, or hair clumping are cosmetic effects of topical application rather than true adverse reactions.

As a member of the isoxazoline class of medications, fluralaner carries class-associated warnings regarding potential neurological adverse reactions. The isoxazoline class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in some animals. These neurological effects have been reported in cats receiving isoxazoline class drugs, including cases in cats without prior history of neurological disorders. While these reactions appear to be rare, their potential severity warrants awareness by cat owners and veterinary professionals.

Serious adverse reactions requiring immediate veterinary attention include seizures or convulsions, severe trembling or muscle twitching, difficulty walking or standing, severe lethargy or weakness, difficulty breathing, or severe allergic reactions. While these effects are uncommon, their occurrence following Bravecto administration should prompt immediate veterinary consultation. Cats with pre-existing neurological conditions may be at increased risk for neurological adverse events and require careful risk-benefit assessment before isoxazoline therapy.

Cat owners should contact their veterinarian if their cat shows any concerning signs following Bravecto administration. The veterinarian can assess whether observed effects are likely treatment-related and determine appropriate management. For non-emergency concerns, monitoring at home may be recommended, while more significant reactions may require veterinary examination. Reporting suspected adverse drug reactions to the manufacturer and FDA helps monitor ongoing safety of veterinary medications.

Fluralaner (Bravecto) has specific contraindications and use restrictions that must be observed to ensure safe treatment. Understanding these limitations helps veterinary professionals identify appropriate candidates for therapy and guides cat owners in recognizing situations where alternative treatments may be more suitable.

Bravecto is contraindicated in cats with known hypersensitivity to fluralaner or any of the inactive ingredients in the product formulation. While true allergic reactions to fluralaner are rare, cats that have experienced hypersensitivity reactions to previous Bravecto applications should not receive subsequent treatments. Signs of hypersensitivity may include facial swelling, hives, severe itching beyond the application site, difficulty breathing, or other allergic manifestations. Alternative flea and tick control methods should be selected for cats with documented fluralaner sensitivity.

Bravecto has not been evaluated for use in kittens younger than six months of age, and the product is not approved for this population. Cats must also meet the minimum weight requirement of 2.6 pounds to receive treatment. These age and weight restrictions ensure that treated cats have adequate body mass and physiological maturity for appropriate drug distribution and metabolism. Young kittens requiring flea control should receive products specifically labeled for their age group.

The safety of Bravecto has not been established in breeding, pregnant, or lactating cats. Reproductive toxicity studies have not been conducted in cats, and use in these populations is not recommended due to insufficient safety data. Queen cats intended for breeding, pregnant cats, and nursing mothers with kittens should receive alternative flea and tick control methods until appropriate safety data becomes available or until they are no longer in breeding, pregnant, or lactating status.

Caution is advised when using Bravecto in cats with a history of neurological disorders, including seizure history. The isoxazoline class of medications has been associated with neurological adverse events, and cats with pre-existing neurological conditions may face elevated risk. Veterinary assessment of the risk-benefit ratio is essential for cats with neurological histories, and alternative flea and tick control methods may be preferred in some cases. If fluralaner is prescribed for cats with neurological histories, enhanced monitoring for adverse effects is advisable.

Drug interaction studies specifically evaluating fluralaner (Bravecto) in cats are limited, though the medication has been used concurrently with many common veterinary pharmaceuticals without documented adverse interactions. Understanding potential interactions helps veterinary professionals make informed treatment decisions for cats receiving multiple medications.

In clinical field studies and post-marketing surveillance, Bravecto has been administered to cats concurrently receiving various medications including vaccines, antiparasitics, antibiotics, and anti-inflammatory drugs without apparent adverse interactions. The manufacturer reports no known drug interactions based on available data. However, as with any medication, informing the veterinarian about all products the cat receives, including prescription medications, over-the-counter products, and supplements, allows comprehensive safety assessment.

Theoretical interactions may exist between fluralaner and other medications affecting the nervous system, given fluralaner's mechanism of action involving GABA receptors in arthropods. While the selective toxicity of isoxazolines for arthropod versus mammalian GABA receptors suggests minimal concern, concurrent use of fluralaner with medications that lower seizure threshold or affect GABA signaling in mammals warrants careful consideration. Cats receiving anticonvulsant medications or other neurologically active drugs should be monitored closely when isoxazoline therapy is initiated.

Bravecto Plus, the combination product containing both fluralaner and moxidectin, requires consideration of interactions relevant to both active ingredients. Moxidectin is a macrocyclic lactone with potential interactions with P-glycoprotein inhibitors that could increase systemic drug exposure. While clinically significant interactions have not been documented in cats, awareness of this theoretical concern is appropriate for cats receiving multiple medications.

Veterinary consultation ensures appropriate medication combinations for cats with complex health needs. The prescribing veterinarian can evaluate all medications the cat receives, consider potential interactions, and recommend monitoring or alternative treatments as needed. For cats receiving multiple antiparasitic products, coordination of treatment schedules helps avoid unnecessary medication overlap while ensuring comprehensive parasite control. Any concerns about medication combinations should be discussed with the veterinarian before initiating or changing treatments.

Important precautions and warnings accompany fluralaner (Bravecto) use to ensure safe and effective treatment. Both veterinary professionals and cat owners should understand these considerations to optimize outcomes and recognize potential concerns requiring attention.

Bravecto is for topical use only and should not be administered orally or by any other route. Oral ingestion of topical fluralaner formulation by cats, whether directly or through grooming of treated animals, may cause adverse effects including salivation and vomiting. Applying the product to the back of the neck where cats cannot reach minimizes grooming-related ingestion. Multi-cat households should separate treated cats until the product has dried to prevent mutual grooming of wet medication.

The neurological warning associated with all isoxazoline class medications warrants careful consideration when prescribing Bravecto. While neurological adverse events appear to be uncommon, their potential severity requires awareness. Neurological adverse reactions including tremors, ataxia, and seizures have been reported in cats receiving isoxazoline class drugs, including cats without prior history of neurological disorders. Cat owners should monitor their pets for any neurological signs following treatment and contact their veterinarian if concerns arise.

Use with caution in cats with a history of neurological abnormalities, as advised in the product labeling. Cats with prior seizures, vestibular disease, or other neurological conditions may face elevated risk of adverse events. The decision to use Bravecto in these patients should involve careful veterinary assessment of the benefits of flea and tick control versus the potential risks associated with isoxazoline therapy. Alternative flea and tick prevention methods may be more appropriate for some cats with significant neurological histories.

Bravecto topical solution has not been shown to be effective for twelve weeks duration in kittens less than six months of age, and the product is not approved for this population. Young kittens requiring flea and tick control should receive age-appropriate products. Similarly, efficacy against American dog ticks extends only eight weeks rather than twelve weeks, which may influence treatment schedules in areas where this tick species is prevalent.

Cat owners should follow all application instructions carefully, including applying to skin rather than hair, avoiding bathing for three days after application, and observing the twelve-week dosing schedule. Proper application technique ensures adequate drug absorption and sustained therapeutic concentrations. Any questions about application or dosing should be directed to the prescribing veterinarian.

Proper storage and handling of Bravecto (fluralaner) maintains product integrity and ensures safe use. The medication should be stored according to label directions to preserve effectiveness throughout its shelf life.

Bravecto topical solution should be stored at temperatures not exceeding 86°F (30°C), which encompasses normal room temperature conditions in most environments. The product should be kept in its original packaging until immediately before use to protect from moisture and maintain the integrity of the single-use applicator system. Exposure to excessive heat, direct sunlight, or moisture may affect product stability and should be avoided.

The single-use applicator tubes are designed for one-time application, and partially used tubes should not be stored for later use. Each tube contains the precise amount of medication for cats within the specified weight range, and the full contents should be applied during a single treatment session. If product leaks from the tube before application, a replacement tube should be obtained to ensure adequate dosing.

Bravecto should be stored out of reach of children and pets to prevent accidental exposure. While the product is designed for topical use in cats, unintended ingestion by children or animals could cause adverse effects. The medication packaging includes child-resistant features, but secure storage in a locked cabinet or high shelf provides additional safety. Empty applicator tubes should be disposed of properly according to local regulations rather than left accessible to curious pets or children.

Handling precautions during application include avoiding direct skin contact with the medication when possible. Wearing gloves during application is advisable for handlers with sensitive skin or known sensitivities to similar products. If skin contact occurs, the affected area should be washed with soap and water. Eye contact should be avoided; if product enters the eyes, they should be flushed thoroughly with water. Hands should be washed after handling the product and applicator.

Unused or expired Bravecto products should be disposed of according to product label directions and local regulations. The medication should not be disposed of in household trash where it might be accessible to animals, nor should it be flushed into wastewater systems. Many veterinary clinics and pharmacies accept unused veterinary medications for proper disposal, and community hazardous waste programs may also accept these products.

Fluralaner (Bravecto) is generally suitable for cats of all breeds, with the medication's weight-based dosing system accommodating the size variation among different feline breeds. The safety and efficacy demonstrated in clinical studies apply broadly across the domestic cat population without documented breed-specific variations in response or tolerance.

No breed-specific contraindications or dosing adjustments for fluralaner have been identified in veterinary literature or manufacturer guidance. The medication has been used successfully in cats representing diverse breeds including Domestic Shorthairs and Longhairs, Persians, Siamese, Maine Coons, and many other breeds without evidence of breed-associated differential response. The physiological processes involved in fluralaner absorption, distribution, metabolism, and excretion do not appear to vary significantly among cat breeds.

Breeds with dense or long coats may require additional attention during topical application to ensure the product contacts skin rather than remaining on the outer hair coat. For breeds such as Persians, Himalayans, Maine Coons, and other long-haired cats, thoroughly parting the fur at the application site before applying the solution ensures proper drug absorption. Visual confirmation that the product has reached the skin surface and is not simply sitting on top of the coat helps ensure effective treatment.

Size variations among cat breeds influence product selection, as fluralaner is dosed by weight rather than breed. Larger breeds such as Maine Coons, Ragdolls, and Norwegian Forest Cats may require the higher-strength formulation (500 mg for cats 13.8 to 27.5 pounds), while smaller breeds and individuals receive appropriately lower doses. Accurate weighing rather than breed-based assumptions ensures correct product selection regardless of breed.

Breed predispositions to neurological conditions warrant consideration given the class-wide neurological warnings for isoxazoline medications. While no breed-specific increased risk of neurological adverse events with fluralaner has been documented, breeds with known predisposition to seizure disorders or other neurological conditions may warrant additional veterinary consideration before prescribing. The decision to use Bravecto in any cat with neurological concerns should involve individualized risk-benefit assessment regardless of breed. Age-related considerations apply across all breeds, with the six-month minimum age requirement applying equally regardless of breed-typical size or maturation rate.

Fluralaner belongs to the isoxazoline class of ectoparasiticides, with several related medications in this class and various alternative approaches available for feline flea and tick control. Understanding the therapeutic options helps veterinary professionals and cat owners select the most appropriate product for individual circumstances.

Lotilaner, marketed as Credelio Cat, is another isoxazoline class medication available for cats. Unlike fluralaner's topical formulation, lotilaner is formulated as an oral chewable tablet administered monthly. This provides an alternative for cats that resist topical application or for owners who prefer oral medication. Lotilaner provides one-month flea and tick protection compared to fluralaner's three-month duration, requiring more frequent administration but offering flexibility in dosing schedule adjustments.

Selamectin (Revolution) and selamectin plus sarolaner (Revolution Plus) represent alternative topical options for feline ectoparasite control. These products provide monthly protection against fleas and, depending on formulation, various ticks and internal parasites. Revolution Plus contains sarolaner, another isoxazoline, combined with selamectin for broad-spectrum protection. Monthly application schedules differ from fluralaner's quarterly dosing, which may influence product selection based on owner preference and compliance considerations.

Fipronil-based products (Frontline) provide another category of topical flea and tick control for cats. While effective, fipronil products typically require monthly application and may have different efficacy profiles against specific tick species compared to isoxazolines. The choice between fipronil and isoxazoline products depends on specific flea and tick control needs, dosing frequency preferences, and individual cat tolerance.

For cats where isoxazoline medications are contraindicated due to neurological concerns, alternative options include fipronil products, selamectin alone (without sarolaner), or insect growth regulator-based approaches. Environmental treatment with methoprene or pyriproxyfen combined with mechanical control measures provides a non-isoxazoline approach to flea management. Veterinary consultation ensures selection of appropriate alternatives when first-line products are unsuitable. No substitution of flea and tick products should occur without veterinary guidance, as products have different spectrums of activity, duration of effect, and safety profiles.